SCHEMBL12377872

SCHEMBL12377872

Cc1c[nH]c2cc(C#N)ccc12

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 3/20 0.48
ATM Q13315 1/20 0.47
IDO1 P14902 1/20 0.47
NR3C1 P04150 1/20 0.44
PGR P06401 1/20 0.44
NR3C2 P08235 1/20 0.44
ALDH1A1 P00352 1/20 0.43
CYP2A6 P11509 1/20 0.43
IMPDH2 P12268 1/20 0.42
IMPDH1 P20839 1/20 0.42
GUSB P08236 2/20 0.41
ITK Q08881 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
BCHE P06276 1/20 0.39
HTR6 P50406 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL733659 0.85 SLC6A4 (0.52) SLC6A4ATMIDO1HTR6
SCHEMBL29994158 0.85 SLC6A4 (0.52) SLC6A4ATMIDO1HTR6
SCHEMBL12352 0.78 ATM (0.56) ATMIDO1NR3C1NR3C2MEN1
SCHEMBL29555842 0.78 ATM (0.56) ATMIDO1NR3C1NR3C2MEN1
SCHEMBL24214245 0.78 IDO1 (0.47) SLC6A4IDO1IMPDH2IMPDH1GUSB
SCHEMBL659621 0.78 IDO1 (0.47) SLC6A4IDO1IMPDH2IMPDH1GUSB
SCHEMBL6039798 0.78 IDO1 (0.47) SLC6A4IDO1IMPDH2IMPDH1GUSB
SCHEMBL11976872 0.78 IDO1 (0.50) SLC6A4IDO1IMPDH2IMPDH1GUSB
SCHEMBL4736477 0.76 KDM4E (0.59) ALDH1A1
SCHEMBL29894052 0.76 KDM4E (0.59) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3484871-B1 PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) SYROS PHARMACEUTICALS INC (US) 2023-06-07 EP disclosed
CN-108101830-B A kind of 3- replaces the preparation method of Oxoindole and derivative 中国科学院成都生物研究所 2019-08-23 CN disclosed
WO-2018013867-A1 INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7) MARINEAU JASON J (US) 2018-01-18 WO disclosed
US-7998954-B2 Pyrimidodiazepinone derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-08-16 US disclosed
US-7998954-B2 Pyrimidodiazepinone derivative KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-08-16 US disclosed
US-20100190775-A1 PYRIMIDODIAZEPINONE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD (JP) 2010-07-29 US disclosed
US-20100190775-A1 PYRIMIDODIAZEPINONE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD (JP) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190775-A1 PYRIMIDODIAZEPINONE DERIVATIVE KCNJ1, KCNJ11, ADRA1D SLC6A4 194/4885ATM 2858/4885IDO1 1557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.